395 related articles for article (PubMed ID: 23588142)
1. Detection of antibodies to anti-TNF agents in psoriatic patients: a preliminary study.
Cozzani E; Burlando M; Parodi A
G Ital Dermatol Venereol; 2013 Apr; 148(2):171-4. PubMed ID: 23588142
[TBL] [Abstract][Full Text] [Related]
2. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
Esposito M; Gisondi P; Cassano N; Ferrucci G; Del Giglio M; Loconsole F; Giunta A; Vena GA; Chimenti S; Girolomoni G
Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
[TBL] [Abstract][Full Text] [Related]
3. Antidrug antibodies in psoriasis: a systematic review.
Hsu L; Snodgrass BT; Armstrong AW
Br J Dermatol; 2014 Feb; 170(2):261-73. PubMed ID: 24117166
[TBL] [Abstract][Full Text] [Related]
4. Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis.
Bito T; Nishikawa R; Hatakeyama M; Kikusawa A; Kanki H; Nagai H; Sarayama Y; Ikeda T; Yoshizaki H; Seto H; Adachi A; Horikawa T; Oka M; Nishigori C
Br J Dermatol; 2014 Apr; 170(4):922-9. PubMed ID: 24329764
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue?
De Simone C; Amerio P; Amoruso G; Bardazzi F; Campanati A; Conti A; Gisondi P; Gualdi G; Guarneri C; Leoni L; Loconsole F; Mazzotta A; Musumeci ML; Piaserico S; Potenza C; Prestinari F
Expert Opin Biol Ther; 2013 Dec; 13(12):1673-82. PubMed ID: 24107126
[TBL] [Abstract][Full Text] [Related]
6. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.
Weinberg JM; Saini R
Cutis; 2003 Jan; 71(1):25-9. PubMed ID: 12553627
[TBL] [Abstract][Full Text] [Related]
7. Association between the type and length of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.
Wu JJ; Poon KY; Bebchuk JD
J Drugs Dermatol; 2013 Aug; 12(8):899-903. PubMed ID: 23986163
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
[TBL] [Abstract][Full Text] [Related]
9. Viewpoint on handling anti-TNF failure in psoriasis.
Bracke S; Lambert J
Arch Dermatol Res; 2013 Dec; 305(10):945-50. PubMed ID: 24096701
[TBL] [Abstract][Full Text] [Related]
10. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
Gniadecki R; Kragballe K; Dam TN; Skov L
Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of TNF-α blocker immunogenicity in psoriatic arthritis.
Zisapel M; Zisman D; Madar-Balakirski N; Arad U; Padova H; Matz H; Maman-Sarvagyl H; Kaufman I; Paran D; Feld J; Litinsky I; Wigler I; Caspi D; Elkayam O
J Rheumatol; 2015 Jan; 42(1):73-8. PubMed ID: 25399390
[TBL] [Abstract][Full Text] [Related]
12. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.
Woolf RT; Smith CH; Robertson K; Barker JN
Br J Dermatol; 2010 Oct; 163(4):889-92. PubMed ID: 20854408
[No Abstract] [Full Text] [Related]
13. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
Leman J; Burden AD
Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811
[TBL] [Abstract][Full Text] [Related]
14. Infections associated with the use of tumor necrosis factor-α inhibitors in psoriasis.
Tan X; Balkrishnan R; Feldman SR
J Drugs Dermatol; 2013 Mar; 12(3):e41-5. PubMed ID: 23545925
[TBL] [Abstract][Full Text] [Related]
15. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study.
Fouache D; Goëb V; Massy-Guillemant N; Avenel G; Bacquet-Deschryver H; Kozyreff-Meurice M; Ménard JF; Muraine M; Savoye G; Le Loët X; Tharasse C; Vittecoq O
Rheumatology (Oxford); 2009 Jul; 48(7):761-4. PubMed ID: 19395543
[TBL] [Abstract][Full Text] [Related]
16. Treatment of generalized vitiligo with anti-TNF-α Agents.
Alghamdi KM; Khurrum H; Taieb A; Ezzedine K
J Drugs Dermatol; 2012 Apr; 11(4):534-9. PubMed ID: 22453596
[TBL] [Abstract][Full Text] [Related]
17. Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis.
Gibellini L; De Biasi S; Bianchini E; Bartolomeo R; Fabiano A; Manfredini M; Ferrari F; Albertini G; Trenti T; Nasi M; Pinti M; Iannone A; Salvarani C; Cossarizza A; Pellacani G
PLoS One; 2016; 11(12):e0167757. PubMed ID: 27936119
[TBL] [Abstract][Full Text] [Related]
18. Anti-TNF agents for the treatment of psoriasis.
Kircik LH; Del Rosso JQ
J Drugs Dermatol; 2009 Jun; 8(6):546-59. PubMed ID: 19537380
[TBL] [Abstract][Full Text] [Related]
19. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
Kalb RE; Blauvelt A; Sofen HL; Chevrier M; Amato D; Calabro S; Wang J; Schenkel B; Gottlieb AB
J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160
[TBL] [Abstract][Full Text] [Related]
20. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
